Document Detail


Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension.
MedLine Citation:
PMID:  8793704     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the contribution of angiotensin-(1-7) [Ang-(1-7)] and prostaglandins to the acute and long-term antihypertensive actions of captopril in mild-to-moderate essential hypertensive patients.
DESIGN AND METHODS: Blood pressure, cardiac rate and the plasma concentrations of angiotensin I (Ang I), angiotensin II (Ang II), Ang-(1-7), prostaglandin E2 and 6-keto prostaglandin F1 alpha (the breakdown product of prostacyclin) were determined in the peripheral venous blood of 24 essential hypertensive subjects before and 3 h after administration of 50 mg captopril. Eleven of 24 patients completed a 6-month treatment period with captopril monotherapy (50 mg twice a day). The hemodynamic and hormonal response produced by a last 50 mg dose of captopril was determined once again in the 11 subjects who maintained blood pressure control with captopril monotherapy for 6 months.
RESULTS: The fall in blood pressure produced 3 h after drug intake was comparable for the first and the last 50 mg captopril dose. Although the first response to captopril increased plasma levels of Ang I only, the response to the last dose of the drug (6 months after) caused significantly higher levels of Ang I and Ang-(1-7). Neither acute nor chronic therapy with captopril had a significant effect on plasma concentrations of Ang II. Although plasma levels of prostaglandin E2 and 6-keto prostaglandin F1 alpha were not modified by a first exposure to captopril, the concentrations of 6-keto prostaglandin F1 alpha but not prostaglandin E2 rose significantly in subjects treated with the inhibitor for 6 months. A negative correlation was also demonstrated between diastolic blood pressure and plasma Ang-(1-7) levels in the 11 essential hypertensive subjects in whom blood pressure was controlled with captopril monotherapy.
CONCLUSIONS: Inhibition of angiotensin converting enzyme with captopril had a significant effect on blood pressure that was not directly accounted for by a suppression of plasma Ang II levels. Continuous therapy with captopril unmasked a contribution of Ang-(1-7) and prostacyclin to the antihypertensive actions of this drug.
Authors:
M Luque; P Martin; N Martell; C Fernandez; K B Brosnihan; C M Ferrario
Related Documents :
9276774 - Protective effect of the angiotensin-converting enzyme inhibitor captopril on postische...
2580164 - Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.
15004434 - Role of angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remod...
1395074 - An indirect evaluation of the effect of the autonomic nervous system following converti...
1399664 - Positioning effects on arterial oxygen and relative pulmonary shunt in patients receivi...
16995754 - Numerical simulation of noninvasive blood pressure measurement.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of hypertension     Volume:  14     ISSN:  0263-6352     ISO Abbreviation:  J. Hypertens.     Publication Date:  1996 Jun 
Date Detail:
Created Date:  1996-12-03     Completed Date:  1996-12-03     Revised Date:  2012-07-03    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  799-805     Citation Subset:  IM    
Affiliation:
Hypertension Unit, San Carlos University Hospital, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Angiotensin II / blood*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Antihypertensive Agents / therapeutic use*
Captopril / therapeutic use*
Epoprostenol / blood*
Female
Humans
Hypertension / blood*,  drug therapy*
Male
Middle Aged
Peptide Fragments / blood*
Time Factors
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Peptide Fragments; 0/angiotensin I (1-7); 11128-99-7/Angiotensin II; 35121-78-9/Epoprostenol; 62571-86-2/Captopril
Comments/Corrections
Comment In:
J Hypertens. 1996 Nov;14(11):1380-1   [PMID:  8934370 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Difference between office and ambulatory blood pressure and response to antihypertensive treatment.
Next Document:  Incidence and risk factors for pneumonia in HIV infected and non-infected drug users.